New cocktail aims to tame dangerous leukemia in High-Risk patients
NCT ID NCT07187505
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether adding venetoclax to the standard two-drug regimen (ATRA and arsenic trioxide) can help patients with a rare blood cancer called acute promyelocytic leukemia (APL) who have very high white blood cell counts. These patients often face serious complications and higher early death rates. The trial will enroll 28 newly diagnosed adults and teens to see if the combination is safe and reduces early deaths.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Venetoclax (a drug that helps leukemia cells die), all-trans retinoic acid (ATRA), and arsenic trioxide (ATO)
- What this could lead to
- If successful, this combination could improve survival and reduce early complications for APL patients with very high white blood cell counts, a group that currently has poor outcomes.
- What could go wrong
- This is a small, early-phase study with only 28 participants and no control group, so results may not apply broadly. Adding venetoclax could also increase side effects like low blood counts or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PROMYELOCYTIC LEUKEMIA (APL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Hematology, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road
Hefei, Anhui, 230022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.